SCY-078 for Invasive Aspergillosis
Patients battling invasive aspergillosis, a serious fungal infection, face unsatisfactory clinical outcomes with mortality rates up to 50% and long treatment durations. Additionally, current therapies are associated with drug-drug interactions, and there is an increasing emergence of A. fumigatus resistance.
We believe SCY-078 may provide improved therapeutic outcomes when added to existing standard of care (azoles). SCY-078's attributes, including strong activity again Aspergillus strains, high lung penetration, convenient oral formulation, and low risk of drug-drug interactions, make it a promising agent to treat invasive aspergillosis.